Literature DB >> 17053932

In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi.

Juliana Saraiva1, Celeste Vega, Mirian Rolon, Rosangela da Silva, Márcio Luis Andrade E Silva, Paulo Marcos Donate, Jairo Kenupp Bastos, Alícia Gomez-Barrio, Sérgio de Albuquerque.   

Abstract

The trypanocidal effect of six lignan lactones, (-)-cubebin (1), (-)-O-methyl cubebin (2), (-)-O-benzyl cubebin (3), (-)-6,6'-dinitrohinokinin (4), (-)-hinokinin (5) and dimethoxymorelensin (6), previously synthesized by our research group, was evaluated in vitro and in vivo. The compounds with higher anti-epimastigote activity were screened against intracellular amastigote of Trypanosoma cruzi. Among these, compound 5 was selected to be assayed in vivo. It was observed that compounds 5, 6 and 2 showed higher trypanocidal activity against epimastigote forms of T. cruzi, displaying inhibitory concentration (IC(50)) values of 0.67, 3.89 and 31.35 muM, respectively. These compounds were also evaluated against intracellular amastigote forms of T. cruzi, with five displaying similar activity to benznidazole. In vivo assays showed significant reduction of parasitaemia after administration of five in mice infected.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053932     DOI: 10.1007/s00436-006-0327-4

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  21 in total

Review 1.  Specific chemotherapy of Chagas disease: controversies and advances.

Authors:  Julio A Urbina; Roberto Docampo
Journal:  Trends Parasitol       Date:  2003-11

2.  Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi.

Authors:  Z BRENER
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1962 Nov-Dec       Impact factor: 1.846

3.  Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi.

Authors:  Vanessa A de Souza; Rosangela da Silva; Ana C Pereira; Vanessa de A Royo; Juliana Saraiva; Marisa Montanheiro; Gustavo H B de Souza; Ademar A da Silva Filho; Marcella D Grando; Paulo M Donate; Jairo K Bastos; Sérgio Albuquerque; Márcio L A e Silva
Journal:  Bioorg Med Chem Lett       Date:  2005-01-17       Impact factor: 2.823

4.  A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase.

Authors:  C Vega; M Rolón; A R Martínez-Fernández; J A Escario; A Gómez-Barrio
Journal:  Parasitol Res       Date:  2005-01-29       Impact factor: 2.289

5.  Evaluation of the trypanocidal activity of lignans isolated from the leaves of Zanthoxylum naranjillo.

Authors:  J K Bastos; S Albuquerque; M L Silva
Journal:  Planta Med       Date:  1999-08       Impact factor: 3.352

6.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.

Authors:  F S Buckner; C L Verlinde; A C La Flamme; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Selective activity of polyene macrolides produced by genetically modified Streptomyces on Trypanosoma cruzi.

Authors:  Miriam Rolón; Elena M Seco; Celeste Vega; Juan J Nogal; José A Escario; Alicia Gómez-Barrio; Francisco Malpartida
Journal:  Int J Antimicrob Agents       Date:  2006-07-17       Impact factor: 5.283

8.  Synthesis and antiprotozoan properties of new 3,5-disubstituted-tetrahydro-2H-1,3,5-thiadiazine-2-thione derivatives.

Authors:  C Ochoa; E Pérez; R Pérez; M Suárez; E Ochoa; H Rodríguez; A Gómez Barrio; S Muelas; J J Nogal; R A Martínez
Journal:  Arzneimittelforschung       Date:  1999-09

9.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.

Authors:  L S Filardi; Z Brener
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

10.  In vitro and in vivo anti-Trypanosoma cruzi activity of a novel nitro-derivative.

Authors:  Susana Muelas-Serrano; Ana Le-Senne; Carlos Fernandez-Portillo; Juan José Nogal; Carmen Ochoa; Alicia Gomez-Barrio
Journal:  Mem Inst Oswaldo Cruz       Date:  2002-06       Impact factor: 2.743

View more
  19 in total

1.  Immunomodulatory and Antileishmanial Activity of Phenylpropanoid Dimers Isolated from Nectandra leucantha.

Authors:  Thais Alves da Costa-Silva; Simone S Grecco; Fernanda S de Sousa; João Henrique G Lago; Euder G A Martins; César A Terrazas; Sanjay Varikuti; Katherine L Owens; Stephen M Beverley; Abhay R Satoskar; Andre G Tempone
Journal:  J Nat Prod       Date:  2015-04-02       Impact factor: 4.050

2.  (-)-Hinokinin-loaded poly(D,-lactide-co-glycolide) microparticles for Chagas disease.

Authors:  Juliana Saraiva; Ana Amélia Moreira Lira; Viviane Rodrigues Esperandim; Daniele da Silva Ferreira; Antônio Sérgio Ferraudo; Jairo Kenupp Bastos; Márcio Luís Andrade E Silva; Cristiane Masetto de Gaitani; Sérgio de Albuquerque; Juliana Maldonado Marchetti
Journal:  Parasitol Res       Date:  2010-01-28       Impact factor: 2.289

3.  Methodological advances in drug discovery for Chagas disease.

Authors:  Juan M Bustamante; Rick L Tarleton
Journal:  Expert Opin Drug Discov       Date:  2011-06       Impact factor: 6.098

Review 4.  Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.

Authors:  Cristina Fonseca-Berzal; Vicente J Arán; José A Escario; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2018-09-19       Impact factor: 2.289

5.  Reduction of parasitism tissue by treatment of mice chronically infected with Trypanosoma cruzi with lignano lactones.

Authors:  Viviane Rodrigues Esperandim; Daniele da Silva Ferreira; Juliana Saraiva; Márcio Luis Andrade Silva; Eveline Soares Costa; Ana Carolina Pereira; Jairo Kenupp Bastos; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2010-05-04       Impact factor: 2.289

6.  Further insights into biological evaluation of new anti-Trypanosoma cruzi 5-nitroindazoles.

Authors:  Cristina Fonseca-Berzal; José Antonio Escario; Vicente J Arán; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2014-01-17       Impact factor: 2.289

7.  In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds.

Authors:  Adriana M C Canavaci; Juan M Bustamante; Angel M Padilla; Cecilia M Perez Brandan; Laura J Simpson; Dan Xu; Courtney L Boehlke; Rick L Tarleton
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

8.  Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase.

Authors:  Mary E Konkle; Tatiana Y Hargrove; Yuliya Y Kleshchenko; Jens P von Kries; Whitney Ridenour; Md Jashim Uddin; Richard M Caprioli; Lawrence J Marnett; W David Nes; Fernando Villalta; Michael R Waterman; Galina I Lepesheva
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

9.  CYP51: A major drug target in the cytochrome P450 superfamily.

Authors:  Galina I Lepesheva; Tatyana Y Hargrove; Yuliya Kleshchenko; W David Nes; Fernando Villalta; Michael R Waterman
Journal:  Lipids       Date:  2008-09-04       Impact factor: 1.880

10.  In vivo infection by Trypanosoma cruzi: a morphometric study of tissue changes in mice.

Authors:  Viviane Rodrigues Esperandim; Daniele da Silva Ferreira; Karen Cristina Sousa Rezende; Wilson Roberto Cunha; Juliana Saraiva; Jairo Kenupp Bastos; Márcio Luis Andrade E Silva; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2012-07-27       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.